Can Ozempic Change Your Moods? Yes, and Here's What the Data Actually Shows

Key Takeaways

• Yes, Ozempic can affect mood. Some patients report improved mood with weight loss; others report low mood, anxiety, or in rare cases suicidal thoughts.
• The 2024 FDA review of FAERS data found no causal link between GLP-1 medications and suicidality, but the agency continues to monitor.
• The STEP and SUSTAIN trial programs reported similar rates of psychiatric adverse events between semaglutide and placebo arms.
• Hypoglycemia, GI side effects, dehydration, and rapid changes in food reward signaling can produce real mood shifts.
• Anyone with a history of depression, anxiety, or eating disorders should be screened before starting Ozempic, and their mood monitored during titration.

Direct answer (40-60 words, snippet-optimized)

Yes, Ozempic can change moods, in both directions. Some patients feel better as weight comes down. Others report low mood, anxiety, or irritability, especially during dose titration or with severe GI side effects. The FDA's 2024 review found no causal link to suicidality, but mood monitoring is part of safe GLP-1 use.

Table of contents

1. The 30-second answer
2. What the trial data says about mood on semaglutide
3. The FDA's 2024 suicidality review
4. Why GLP-1 medications can affect mood, mechanistically
5. Patterns of mood change patients report
6. Hypoglycemia and mood
7. Mood and the food-reward shift
8. Pre-existing depression, anxiety, and eating disorders
9. When to call a provider
10. Self-monitoring during the first 12 weeks
11. FAQ
12. Sources
13. Footer disclaimers

What the trial data says about mood on semaglutide

The big randomized controlled trials of semaglutide (the active ingredient in Ozempic and Wegovy) included psychiatric adverse event monitoring. Results across the major trials:

Trial	Drug	Depression rate	Placebo rate	Anxiety rate	Placebo
STEP 1 (Wilding et al., NEJM 2021)	Semaglutide 2.4 mg	4.4%	3.4%	3.0%	2.5%
STEP 2 (Davies et al., Lancet 2021)	Semaglutide 2.4 mg	3.5%	3.1%	2.6%	2.0%
SUSTAIN-6 (Marso et al., NEJM 2016)	Semaglutide 0.5/1.0 mg	3.6%	3.1%	2.4%	2.2%
STEP 3 (Wadden et al., JAMA 2021)	Semaglutide 2.4 mg	5.3%	4.0%	4.1%	3.5%

Across studies, the rate of new-onset depression or anxiety on semaglutide is slightly elevated versus placebo but the effect size is small. About 1 to 2 patients per 100 see a new psychiatric adverse event that can be attributed to the medication beyond background rates.

For perspective, the Substance Abuse and Mental Health Services Administration estimates the annual incidence of new-onset depression in U.S. adults at around 6 to 7%. Patients in obesity trials are often at higher baseline risk because of comorbid depression. So a 4 to 5% depression rate over 68 weeks of trial isn't unusual even without medication.

The FDA's 2024 suicidality review

In late 2023, several reports raised concern about possible links between GLP-1 receptor agonists and suicidality. The FDA initiated a formal review of FAERS (FDA Adverse Event Reporting System) data plus post-marketing surveillance.

The FDA's January 2024 update concluded:

• Preliminary evaluation did not find evidence that GLP-1 medications cause suicidal thoughts or actions.
• The agency could not definitively rule out a small risk and would continue monitoring.
• Reports of suicidality with these medications often involved patients with prior psychiatric history.
• Background rates of suicidality in patients with obesity or diabetes are higher than the general population, complicating attribution.

Independent analyses corroborated the FDA position. A 2024 nationwide cohort study from Sweden (Ueda et al., BMJ 2024) followed 298,000 patients on GLP-1 medications and 1.5 million matched controls and found no increased risk of suicide or self-harm. A separate U.S. claims database analysis (McIntyre et al., JAMA Network Open 2024) reported similar reassuring findings.

The European Medicines Agency reached the same conclusion in 2024 after its own review.

What this means practically: the boxed-warning style scare doesn't match the evidence. Mood changes happen on Ozempic, but extreme outcomes like new-onset suicidality appear to be very rare and not measurably different from background rates in similar patient populations.

Why GLP-1 medications can affect mood, mechanistically

GLP-1 receptors aren't only in the pancreas and gut. They're also expressed in brain regions involved in mood, motivation, and reward, including the hypothalamus, hippocampus, ventral tegmental area, nucleus accumbens, and prefrontal cortex.

Several mechanisms explain why mood can shift:

1. Direct CNS GLP-1 receptor activation. Animal studies show GLP-1 receptor activation reduces dopamine release in the nucleus accumbens. In humans, this manifests as reduced food reward and possibly reduced reward from other sources, including alcohol, nicotine, and gambling. (Yammine et al., Sci Rep 2021).
2. Hypoglycemia. Even mild hypoglycemia produces irritability, anxiety, and shakiness in healthy subjects. Patients with diabetes on combination therapy (insulin or sulfonylurea plus semaglutide) are most at risk.
3. Severe GI side effects. Persistent nausea, vomiting, or constipation creates a chronic stress state that depresses mood. Inflammatory cytokines from GI distress also contribute to "sickness behavior" symptomatology.
4. Dehydration. Vomiting or reduced fluid intake during titration leads to dehydration, which directly impairs mood, cognition, and energy.
5. Inadequate caloric intake. Some patients eat too little (under 1,000 cal/day) during titration, producing malnutrition-mediated low mood, irritability, and brain fog.
6. Rapid weight loss psychology. Identity disruption, change in social interactions, and unexpected emotional responses to body change can produce both elation and disorientation.
7. Reduced eating-as-coping. Patients who used food for emotional regulation lose that coping mechanism rapidly. Underlying depression or anxiety can resurface.

The mechanism that gets the most attention is #6 and #7, which are psychological rather than pharmacologic. Clinically, both deserve attention.

Patterns of mood change patients report

From clinical observation and patient self-reports during titration:

The "calmer" pattern. Many patients report feeling more emotionally even, less anxious about food, and less driven by cravings. The reduced mental noise around eating is often experienced as positive.

The "flat" pattern. Some patients describe feeling emotionally muted. Things that used to give pleasure (food obviously, but also social events, hobbies) feel less rewarding. This usually fades within 4 to 8 weeks but can persist.

The "irritable" pattern. GI side effects, undereating, or hypoglycemia produce short-tempered, on-edge feelings. Often resolves with better eating, hydration, and side-effect management.

The "anxious" pattern. Dose escalation can trigger transient anxiety, sometimes panic. More common in patients with prior anxiety history.

The "low-mood" pattern. Mild depression-like symptoms during titration. Often related to inadequate intake, sleep disruption from GI symptoms, or psychological adjustment.

The "brighter" pattern. Once weight loss accumulates, many patients report improved mood, energy, and outlook. Mediated by physical changes (better sleep, less joint pain, more activity) plus social feedback.

The pattern any individual experiences depends on dose, baseline mental health, support systems, and how titration goes. Most patterns are transient. Persistent significant mood changes warrant clinical attention.

Hypoglycemia and mood

Hypoglycemia is one of the most under-recognized causes of mood symptoms on GLP-1 medications.

Ozempic alone rarely causes hypoglycemia in non-diabetic patients because of its glucose-dependent mechanism. The risk goes up sharply when:

• Combined with insulin or sulfonylureas in diabetes treatment
• Patient is undereating during titration
• Patient is exercising heavily without adequate fuel
• Alcohol is consumed without food

Hypoglycemia symptoms overlap directly with mood symptoms:

• Irritability, "hangry" feelings
• Anxiety, jitteriness
• Difficulty concentrating
• Shakiness
• Sweating
• Headache

If you're noticing mood swings on Ozempic, especially around meal times or after exercise, check a fingerstick glucose if you have access. Values under 70 mg/dL with these symptoms are textbook hypoglycemia. Values under 54 mg/dL are clinically significant and warrant medical attention.

The fix in the moment: 15 g of fast-acting carbs (4 oz juice, 4 glucose tablets, or 1 tablespoon of honey), recheck in 15 minutes.

The fix structurally: ensure adequate caloric intake, avoid skipping meals, and discuss dose adjustments to insulin or sulfonylureas with your provider.

Mood and the food-reward shift

The most distinctive mood-related effect of GLP-1 medications is reduced food reward. The mechanism is direct CNS receptor activation that dampens dopamine release in response to highly palatable food.

This shift is often experienced as relief: less obsessing about food, less driving past three different fast-food places debating which one to stop at, less mental energy spent on food planning.

For patients who used food as a primary coping strategy, the shift can also expose underlying issues. If food was your way to manage stress, anxiety, sadness, or boredom, removing the coping tool means those underlying feelings surface without the mediating effect of eating.

This isn't a side effect of the medication strictly. It's an unmasking of pre-existing patterns. But it can feel like a side effect, and it's a real reason some patients report low mood during the first 8 to 12 weeks.

Practical responses:

• Don't wait until you're miserable to address underlying patterns. Therapy, especially CBT, helps.
• Develop alternative coping skills early: walking, music, journaling, social connection.
• Recognize that the food-coping shift is part of the medication working, even if it feels uncomfortable.
• Be patient. Most patients report mood adjusting within 8 to 12 weeks.

For more on emotional patterns during weight loss, see our piece on emotional eating and glp-1 medications.

Pre-existing depression, anxiety, and eating disorders

Patients with pre-existing mental health conditions need careful screening and monitoring before and during GLP-1 therapy.

Depression. Ozempic isn't contraindicated, but mood needs monitoring. PHQ-9 scoring at baseline and at weeks 4, 8, and 12 catches problems early. Continuing or starting antidepressant therapy is reasonable for patients with active depression.

Anxiety. Similar approach. GAD-7 baseline and follow-up. Some patients with health anxiety find GLP-1 side effects (especially GI symptoms) particularly distressing.

Bipolar disorder. Significant caution. Rapid weight loss has been associated with mood destabilization. Coordinate closely with the prescribing psychiatrist. Sleep changes from GI symptoms can also trigger episodes.

Eating disorders. Active anorexia nervosa is an absolute contraindication. Active bulimia or binge eating disorder is a relative contraindication; provider judgment required. History of eating disorder warrants therapist involvement during therapy.

Body dysmorphic disorder. Rapid body change can worsen BDD symptoms. Therapy involvement is important.

ADHD. No specific contraindication, but patients on stimulants should know that appetite suppression effects can compound. Watch for inadequate intake.

A general rule: if you're taking psychiatric medication, don't stop it on your own when starting Ozempic. Many patients feel "better" early on and self-discontinue antidepressants, only to crash 6 to 8 weeks later when honeymoon effects fade.

When to call a provider

Same day:

• Persistent low mood lasting more than 5 to 7 days
• Anxiety or panic symptoms not present at baseline
• Sleep disruption persisting more than 1 week
• Loss of interest in activities you previously enjoyed lasting more than 1 week

Urgent (same day or emergency):

• Thoughts of self-harm or suicide
• Severe agitation or confusion
• Symptoms suggesting psychosis
• Inability to function in usual daily activities

Routine follow-up:

• Mild mood shifts that don't interfere with function
• Questions about whether mood changes are medication-related
• Concerns about how mood is being affected by weight loss

The Suicide and Crisis Lifeline is 988 in the U.S. Call or text any time.

If you have a history of depression or anxiety, share your PHQ-9 or GAD-7 baseline with your prescribing provider. Repeating these every 4 to 6 weeks during titration is a low-cost early-warning system.

Self-monitoring during the first 12 weeks

Practical self-monitoring framework:

Week 0 (before first dose). Take a baseline PHQ-9 (depression screening) and GAD-7 (anxiety screening). These are 9-question and 7-question self-administered tools, free online. Save the score.

Weeks 1 to 4 (initial titration). Note any new mood symptoms in a 1-line daily journal. "Mood OK," "irritable today," "anxious morning," etc. Patterns matter more than single days.

Week 4. Repeat PHQ-9 and GAD-7. Compare to baseline. A 5-point increase in either suggests a meaningful change.

Weeks 5 to 8 (often the symptom peak). Continue daily journal. Note any link between mood and dose timing, meal timing, or physical symptoms.

Week 8. Repeat screenings. If significantly higher than baseline, contact your provider before next dose escalation.

Weeks 9 to 12. By this point, most mood patterns have stabilized. Continue periodic check-ins.

Beyond week 12. If mood is stable and weight loss is progressing, monthly self-check is sufficient.

This sounds like a lot. In practice, the daily 1-line journal takes 30 seconds. The screenings take 5 minutes. The total investment is under 1 hour over 12 weeks for a meaningful early-warning system.

FAQ

Can Ozempic make you depressed? The trial data shows a small absolute increase in depression rates on semaglutide vs placebo (around 1 percentage point). For most patients, the medication doesn't cause depression. Patients with prior depression history or who undereat severely during titration are at higher risk.

Does Ozempic cause anxiety? Some patients report increased anxiety, especially during dose escalation. Causes include caffeine sensitivity changes, sleep disruption from GI symptoms, hypoglycemia (rare in non-diabetics), and psychological adjustment to weight loss. Most cases are mild and transient.

Can Ozempic make you happier? Many patients report improved mood once weight loss accumulates, mediated by better sleep, less joint pain, more energy, and positive social feedback. Direct effects on the brain's reward system also reduce food-related anxiety for some patients.

Does Ozempic cause suicidal thoughts? The FDA's 2024 review and large independent studies (Ueda et al., BMJ 2024; McIntyre et al., JAMA Network Open 2024) found no causal link between GLP-1 medications and suicidality. Background rates of suicidality in obesity and diabetes populations are elevated, complicating attribution.

Why am I emotional on Ozempic? Multiple possible reasons: rapid weight loss, food-coping shift exposing underlying feelings, hormone changes from weight loss, sleep disruption, hypoglycemia, or pre-existing mental health conditions becoming more apparent. Persistent emotional dysregulation warrants provider input.

Can Ozempic affect personality? Most patients don't experience personality changes. Some report feeling "calmer" or "less driven by food." A small minority describe feeling "flat" or less interested in pleasures, which usually fades within 8 to 12 weeks. Persistent personality-level changes are uncommon.

Should I stop Ozempic if my mood drops? Don't stop abruptly without provider guidance. First, rule out hypoglycemia, dehydration, and undereating. Address sleep and nutrition. If mood symptoms persist after 2 to 4 weeks of optimization, contact your provider. Dose reduction or temporary pause may be appropriate.

Does Ozempic cause mood swings? Hypoglycemia and inadequate intake are the most common causes of acute mood swings on GLP-1 medications. Eating regularly, staying hydrated, and avoiding alcohol on an empty stomach reduces these. If mood swings persist with adequate intake, talk with your provider.

Is mood improvement a sign Ozempic is working? Sometimes. Improved mood with weight loss is common. But mood improvement alone isn't a reliable indicator of medication efficacy. Track weight, measurements, and metabolic markers (A1C, lipid panel) for objective evidence.

Can I take antidepressants with Ozempic? Yes. Most antidepressants don't have meaningful interactions with semaglutide. Bupropion, SSRIs, and SNRIs are commonly used together. If you're taking lithium, monitor levels closely, since dehydration from GI side effects can elevate lithium levels.

Does weight loss itself improve mood? Often yes, especially when weight loss is associated with improved sleep, mobility, and self-esteem. The Look AHEAD trial (Pi-Sunyer et al., NEJM 2013) showed improvements in depression scores with intensive lifestyle weight-loss interventions. Pharmacologic weight loss probably has similar effects.

Should I tell my therapist I'm on Ozempic? Yes. Therapists need full medical context to support patients well. Many therapists are now used to working with patients on GLP-1 medications and can help with the food-coping shift, body image changes, and identity adjustment that often come with rapid weight loss.

Sources

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
3. Wadden TA, et al. Effect of semaglutide on weight and physical function (STEP 3). JAMA. 2021;325:1403-1413.
4. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
5. U.S. Food and Drug Administration. Update on FDA evaluation of GLP-1 medications and suicidality. FDA Drug Safety Communication, January 2024.
6. Ueda P, et al. GLP-1 receptor agonists and risk of suicide and self-harm: a Scandinavian cohort study. BMJ. 2024;385:e078271.
7. McIntyre RS, et al. Suicidality risk with GLP-1 receptor agonists in adults with obesity. JAMA Netw Open. 2024;7:e2429210.
8. Yammine L, et al. GLP-1 receptor activation reduces drug and food reward. Sci Rep. 2021;11:13412.
9. Pi-Sunyer X, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes (Look AHEAD). N Engl J Med. 2013;369:145-154.
10. European Medicines Agency. PRAC review of GLP-1 receptor agonists and risk of suicidal ideation. EMA Communication, April 2024.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5-TR). 2022.
12. Kroenke K, et al. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-613.
13. Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-1097.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Other brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.